SKAN Group AGXSWX:SKAN +2.16%82 EBITDA Margin % is 16.81% as of Dec. 2025, which is 24% above its 10-year median of 13.51. GuruFocus rates XSWX:SKAN with a GF Score™ of 82/100 and a GF Value™ of CHF85.80 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 813 Medical Devices & Instruments companies, SKAN Group AG ranks better than 56.7% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. SKAN Group AG's EBITDA for the
six
months ended in Dec. 2025 was CHF33.4 Mil. SKAN Group AG's Revenue for the
six
months ended in Dec. 2025 was CHF198.8 Mil. Therefore, SKAN Group AG's EBITDA margin for the quarter that ended in Dec. 2025 was 16.81%.
SKAN Group AG (XSWX:SKAN) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
SKAN Group AG EBITDA Margin % Related Terms
SKAN Group AG EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for SKAN Group AG's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:SKAN vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, SKAN Group AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SKAN Group AG EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SKAN Group AG's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where SKAN Group AG's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SKAN Group AG (XSWX:SKAN) has a EBITDA Margin % of 16.81% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SKAN Group AG and its competitors. This is 24% above median its historical median of 13.51. Over the past decade, SKAN Group AG's EBITDA Margin % has ranged from 10.15 to 16.52. According to the industry distribution chart, SKAN Group AG ranks #352 out of 813 companies in the Medical Devices & Instruments industry, placing it in the top 43.3%.
Is SKAN Group AG's EBITDA Margin % too high?
SKAN Group AG's current EBITDA Margin % of 16.81% is 24% above median its 10-year median of 13.51. Over the past 10 years, this metric has ranged from a low of 10.15 to a high of 16.52. The Medical Devices & Instruments industry median EBITDA Margin % is 7.47. SKAN Group AG's value of 16.81% is 125% above this industry median. Based on the distribution chart, SKAN Group AG ranks #352 out of 813 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, SKAN Group AG has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SKAN Group AG's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, SKAN Group AG ranks #352 out of 813 companies for EBITDA Margin %. This puts SKAN Group AG in the upper half of its industry. The industry median EBITDA Margin % is 7.47. SKAN Group AG's value of 16.81% is 125% above this benchmark. Historically, SKAN Group AG's own EBITDA Margin % has ranged from 10.15 to 16.52 over the past decade. While the company's 10-year median is 13.51 vs. the industry median of 7.47, SKAN Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.47, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SKAN Group AG's current EBITDA Margin % of 16.81% is 125% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SKAN Group AG and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SKAN Group AG's current EBITDA Margin % is 16.81%, which is 24% above median its own 10-year median of 13.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SKAN Group AG stock overvalued right now?
Based on GuruFocus' analysis, SKAN Group AG (XSWX:SKAN) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF85.80, compared to a current price of CHF56.80 — trading 33.8% below its estimated fair value. The current EBITDA Margin % is 16.81%, which is 24% above median its 10-year median of 13.51 and 125% above the Medical Devices & Instruments industry median of 7.47. SKAN Group AG's overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For SKAN Group AG (XSWX:SKAN), the current EBITDA Margin % is 16.81% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SKAN Group AG (XSWX:SKAN) Overvalued in 2026?
Based on GuruFocus' analysis, SKAN Group AG stock appears to be undervalued.
The current stock price of CHF56.80 is trading 33.8% below its estimated GF Value™ of CHF85.80.
GuruFocus considers SKAN Group AG to be Significantly Undervalued.
Key valuation signals for XSWX:SKAN:
EBITDA Margin %: 16.81% (24% above median its 10-year median of 13.51)
GF Value™: CHF85.80 vs. price of CHF56.80 (33.8% below fair value)
Industry Position: 125% above the Medical Devices & Instruments median (#352 of 813)
No single metric tells the full story. See the XSWX:SKAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SKAN Group AG is a market and technological company for isolators, cleanroom devices, and decontamination processes for the aseptic production of biopharmaceutical substances. The company offers its customers process support, services, and consumables. Its products include biological indicators, isolators, Laboratory/cleanroom equipment, laminar flow, safety workbenches, transfer systems, and others. The Firm has three operating segments: Equipment & solutions, Services & Consumables, and Other. The company generates the majority of its revenue from the Equipment & solutions segment. Geographically, the company derives revenue from Asia, Europe, Americas, and Other regions.
82GF Score
Get the complete analysis for XSWX:SKAN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:SKAN has been successfully added to your 
